Urology

 Prostate biopsies are performed when results from initial tests, like a prostate-specific antigen (PSA) blood test or digital rectal exam, indicate the possibility of prostate cancer. A range of tissue samples are extracted with a needle from the prostate gland and are analyzed under a microscope using a Hematoxylin & Eosin stain, and in some cases, immunohistochemical stains to identify cancerous cell abnormalities. If cancer is present, it can be localized to the exact region of the prostate from the location of the tissue extraction. 

This FISH test is designed to detect aneuploidy for chromosomes 3, 7, and 17 and loss of the 9p21 locus, via fluorescence in situ hybridization (FISH) in urine specimens from persons with hematuria suspected of having bladder cancer. Results are intended for use in conjunction with, and not in lieu of, current standard diagnostic procedures (urine cytology) as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.

 UTIDX™ is a urine based test designed to identify pathogens commonly associated with recurrent or persistent urinary tract infections while determining the best treatment options for the patient.  Utilizing PCR technology, we are able to detect the presence of pathogens as well as the presence of antibiotic resistant genes.  PCR is paired with our internally validated methods for testing Antibiotic Sensitivity Testing of the identified pathogens to ensure personalized therapy options for the patient.

Uro17™ is a urine-based biomarker test to detect bladder cancer in people with symptoms of bladder cancer. It is also used to monitor for recurrence during treatment follow up.  The innovative aspect is that it is a non-invasive diagnostic tool that detects bladder cancer based on the novel biomarker keratin 17 (K17). It can help stratify patients with suspected bladder cancer and prioritize them for further secondary care investigations